NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Recruiting

• Conditions: Gout Arthritis

• Registration Number: NCT05744297
• Lead Sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon

Brief Summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production.

However pathogenesis of acute gout flares remains poorly known in vivo in human.

The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Detailed Description

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

Study Timeline

• Status Verified: 2023-02
• Study First Submitted: 2023-02-02
• Study First Submitted QC: 2023-02-22
• Study First Posted: 2023-02-27
• Study Start: 2023-04-28
• Last Update Submitted: 2023-05-11
• Last Update Posted: 2023-05-12
• Primary Completion: 2023-06
• Study Completion: 2023-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score > 8
• Aged > 18

Exclusion Criteria

• Gout treatment already started
• Inflammatory Arthritis other than Gout Arthritis
• Pregnant or breast feeding women
• Patient protected by law

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
NLRP3 inflammasome activation in white blood cells.	Patient admission at hospital	White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.

Secondary Outcome Measures

Name	Time	Method
NLRP3 inflammasome activation in synovial cells.	Patient admission at hospital	Nucleated cells will be isolated from synovial fluid sample and NLRP3 inflammasome activation will be assessed by flow cytometry.
Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells	up to 7 days after analysis of NLRP3 activity	NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity in blood or synovial fluid.

Trial Locations

Locations (1)

Centre Hospitalier Saint Joseph Saint Luc; 🇫🇷 Lyon, France